Regeneron Pharma (REGN) PT Raised to $750 at Cowen

Cowen analyst Tyler Van Buren raised the price target on Regeneron Pharma (NASDAQ: REGN) to $750.00 (from $655.00) while maintaining a Market Perform rating.

The analyst commented, "In conjunction with the Cowen Biotech team's Q3 earnings preview, we are updating our REGN model. Q3 revenue is virtually unchanged, but OpEx was increased resulting in our new EPS est of $10.10. More importantly, we are increasing our out-year Eylea ests following the recent HD Eylea data to reflect a ~20% decline by 2026 (-35% prior). This results in an increase in our PT to $750 from $655."

You May Also Be Interested In

• MarineMax (HZO) PT Lowered to $35 at Stifel
• Regeneron (REGN) and Mammoth Biosciences Collaborate over Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
• Tyler Tech (TYL) PT Raised to $500 at Oppenheimer